Biotech Series C Investors & VC Firms
600 firms in this list, with a median first check of $1M. 112 of them lead rounds. Generated from verified public data and updated continuously.
Longbow Capital LLP
NorwichSeries C–Late Stage$1.3M – $12.7M
2 people
Vincera Capital
TaipeiSeed–Late Stage$500K – $10M
2 people
Nissay Capital
TokyoPre-Seed–Late Stage$610K – $71M
1 person
Japan Asia Investment
TokyoPre-Seed–Late Stage$1M – $10M
1 person
Kenson Ventures, LLC
Menlo ParkSeed–Late Stage$500K – $3M
1 person
BioTrack Capital
Grand CaymanSeed–Late Stage
4 people
SymBiosis
BentonvilleSeed–Late Stage
4 people
CIBC
ChicagoPre-Seed–Late Stage$1.5M – $29.2M
Ameba Capital
ShanghaiSeed–Late Stage
3 people
Cdh Venture Management Company Limited
Hong KongSeed–Late Stage$7.1M – $300M
CDIB Capital
Hong KongSeries A–Series C$1.5M – $100M
Company K Partners
SeoulSeed–Late Stage$2.2M – $44M
ePlanet Capital
San JoseSeed–Late Stage
3 people
GVFL Ltd.
AhmedabadSeed–Late Stage$250K – $25M
Harriet Ventures
Series A–Growth$500K – $50M
Hong Kong Science and Technology Parks – incubation programs
Hong KongPre-Seed–Growth$13K – $100M
MSD Global Health Innovation Fund
RahwaySeries A–Late Stage$1M – $30M
Oriza Holdings
SuzhouSeed–Growth$1.7M – $200M
Quam Venture Capital
Pre-Seed–Growth$500K – $10M
SL Investment Ltd.
SeoulSeries A–Late Stage$500K – $2M
West Virginia Jobs Investment Trust
CharlestonSeed–Late Stage$100K – $1M
Yuanta Investment
SeoulSeed–Late Stage$1M – $15M
BSK Investment
SeoulSeed–Late Stage
2 people
Hanne Capital
ShanghaiSeed–Late Stage
2 people
Related lists
Series C Investors & VC Firms (2751)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Biotech Series A Investors & VC Firms (1596)Biotech Investors & VC Firms in United States (1039)Series C Investors & VC Firms in United States (946)Biotech Series B Investors & VC Firms (900)Series C Investors & VC Firms in Global (896)Biotech Pre-Seed Investors & VC Firms (896)Healthtech Series C Investors & VC Firms (771)
Data sourced from public filings and firms' own websites — see our methodology.